Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04040296 · ClinicalTrials.gov registry record · NA
Personalized Recommendations for Acute Kidney Injury (AKI) Care
A NA study of Acute Kidney Injury, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 4,003
- Enrollment target
- 1
- Study location
NCT04040296: Completed NA study of Acute Kidney Injury, sponsored by Yale University.
NCT04040296 is a NA study of Acute Kidney Injury that has completed, run by Yale University. The registered enrollment target is 4,003 participants, above the 2,277-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04040296, a NA study of Acute Kidney Injury, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,003 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized clinical trial of a "Kidney Action Team", which will provide timely, personalized recommendations for the diagnosis and initial treatment of hospitalized patients with Acute Kidney Injury (AKI).
Primary Outcome
Progression of AKI is defined by an increase in KDIGO creatinine stage from that present at the time of randomization. Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments (for the purpose of volume removal) will not be included. Mortality will be determined from hospital administrative records. The rates of the primary outcome will be compared between the study arms using the Cochrane-Mantel-Haens
Conditions Studied
Interventions
- OTHER Kidney Action Team Recommendations
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,003 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2024-02-22 |
| Phase | NA |
What the finished NCT04040296 record still lists
NCT04040296 is an interventional study that assigns participants to a tested intervention. Its 4,003 participants enrollment target places it among the larger protocols in the corpus, above the 2,277-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which Kidney Action Team Recommendations is the first listed.
NCT04040296 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04040296 about?
NCT04040296 is a clinical study titled "Personalized Recommendations for Acute Kidney Injury (AKI) Care". This is a randomized clinical trial of a "Kidney Action Team", which will provide timely, personalized recommendations for the diagnosis and initial treatment of hospitalized patients with Acute Kidney Injury (AKI).
What is the current status of trial NCT04040296?
This trial is currently completed. It is a NA study. The enrollment target is 4,003 participants. The study started on 2021-10-29. Estimated completion is 2024-02-22.
What conditions does trial NCT04040296 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT04040296?
The interventions under investigation include: Kidney Action Team Recommendations (OTHER).
Who is sponsoring clinical trial NCT04040296?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04040296 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04040296's enrollment target sits among peer trials
4,003 6th of 74 higher than 69 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
-
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
CTSN Embolic Protection Trial
RECRUITING · NA
-
A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
RECRUITING · NA
-
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI